Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Conditions
Interventions
MSDC-0602K
Placebo
Locations
43
United States
Chandler, Arizona, United States
Tucson, Arizona, United States
Chula Vista, California, United States
Fresno, California, United States
Garden Grove, California, United States
Huntington Park, California, United States
Start Date
September 14, 2016
Primary Completion Date
June 1, 2019
Completion Date
June 1, 2019
Last Updated
September 16, 2020
NCT07265544
NCT07403604
NCT06819917
NCT07221227
NCT06218589
NCT06661655
Lead Sponsor
Cirius Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions